BioElectronics Files FDA Application for Treatment of Musculoskeletal Pain

FREDERICK, MD, July 12, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that a Traditional 510(k) Premarket Notification for ActiPatch® was filed today with the U.S. Food and Drug Administration (FDA). The market clearance requested was “over-the-counter adjunctive use in the treatment of musculoskeletal pain”. While ActiPatch is already FDA-cleared for … Continue Reading

BioElectronics Corporation’s President Andy Whelan Joins Everett Jolly on “Stock Day” to Discuss Progress

PHOENIX, June 13, 2018 (GLOBE NEWSWIRE) — Uptick Newswire welcomed Andy Whelan, President of BioElectronics Corporation (OTC Pink:BIEL) (“the Company”) back onto the “Stock Day” podcast. Andy spoke with Everett about their progress in the US market, UK market, the new product, the US FDA, and new distributors and potential partnership opportunities. BioElectronics Corporation is … Continue Reading